Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of a single dose of RSV mRNA vaccine in adults aged 50 years and older
CTR20252307Phase 2Active
- Sponsor
- Afana Biotechnology
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Sinovac RSV mRNA vaccine in respiratory syncytial virus disease (RSV), sponsored by Afana Biotechnology. Started Jun 2025; status: active.
02
Drugs
Sinovac RSV mRNA vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20252307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252307.